IQVIA Holdings Inc (IQV) stock surged 5.02% in pre-market trading on Wednesday, following the company's release of its first-quarter 2025 earnings results. The healthcare data and analytics provider delivered strong revenue and profit figures, beating expectations and showcasing robust growth in its Real-World Evidence (RWE) segment.

According to the earnings call highlights, IQVIA reported total revenue for the first quarter exceeding guidance, with the Technology and Analytics Solutions (TAS) segment showing particularly impressive growth. Revenue in this segment increased by 6.4% reported and 7.6% at constant currency, driven by double-digit growth in real-world evidence. This performance underscores IQVIA's strong position in the healthcare analytics market and its ability to capitalize on the growing demand for real-world data in drug development and commercialization.

Despite challenging market conditions, including delayed decision-making by customers and a deteriorating funding environment for emerging biopharma companies, IQVIA demonstrated resilience. The company's backlog reached a new record of $31.5 billion, growing 4.8% compared to the prior year, indicating strong future demand for its services. Additionally, IQVIA is making progress in deploying AI agents, which have shown positive results and productivity gains, potentially positioning the company for further growth and efficiency improvements in the coming quarters.